Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients

Anna Vanazzi, Chiara Grana, Daniele Laszlo, Marco Chinol, Mara Negri, Liliana Calabrese, Giovanni Paganelli, Giovanni Martinelli

Blood (2012) 120 (21): 4876.

https://doi.org/10.1182/blood.V120.21.4876.4876

Published: 2012

Journal Articles

Efficacy of 90 yttrium-Ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma,

Anna Vanazzi, Chiara Grana, Cristiano Crosta, Giancarlo Pruneri, Stefania Rizzo, Davide Radice, Antonello Pinto, Liliana Calabrese, Mara Negri, Giovanni Paganelli, Giovanni Martinelli, MD

Blood (2011) 118 (21): 3713.

https://doi.org/10.1182/blood.V118.21.3713.3713

Published: 2011

Journal Articles

A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study

Simona Sammassimo, Alberto Agazzi, Simona Bassi, Liliana Calabrese, Paola Bertazzoni, Anna Vanazzi, Angelo Gardellini, Federica Gigli, Giovanna Andreola, Giovanni Martinelli, MD

Blood (2010) 116 (21): 5030.

https://doi.org/10.1182/blood.V116.21.5030.5030

Published: 2010

Journal Articles

90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.

Anna Vanazzi, MD, Alessandra Alietti, MD, Alberto Agazzi, MD, Mara Negri, Maria Teresa Lionetti, Aleksandra Babic, Davide Radice, Luca Nassi, MD, Simona Sammassimo, MD, Cristina Rabascio, Pierluigi Antoniotti, Lara Roveda, Bruno Lucchetti, Tiziana Suardi, Alessio Piredda, Liliana Calabrese, Giovanni Martinelli, MD, Daniele Laszlo, MD

Blood (2009) 114 (22): 3210.

https://doi.org/10.1182/blood.V114.22.3210.3210

Published: 2009

Journal Articles

Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma

Anna Vanazzi, Pier Francesco Ferrucci, Chiara Maria Grana, Giancarlo Pruneri, Cristiano Crosta, Antonello Pinto, Marco Chinol, Liliana Calabrese, Giovanni Paganelli, Giovanni Martinelli

Blood (2008) 112 (11): 3063.

https://doi.org/10.1182/blood.V112.11.3063.3063

Published: 2008

Journal Articles

Rituximab and 2-Cda Activity in CLL/SLL Patients: An Update of Pharmacogenomic and Clinical Results

Paola Bertazzoni, Cristina Rabascio, Liliana Calabrese, Federica Gigli, Simona Bassi, MD, Luca Nassi, Simona Sammassimo, Sara Steffanoni, Davide Radice, Angelica Calleri, Emilia Cocorocchio, Daniele Laszlo, Giovanni Martinelli

Blood (2008) 112 (11): 3171.

https://doi.org/10.1182/blood.V112.11.3171.3171

Published: 2008

Journal Articles

Interim 18 f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma

Federica Gigli, Luca Nassi, Mara Negri, Laura Travaini, Sara Steffanoni, Sarah Jane Liptrott, Patrizia Mancuso, Paola Bertazzoni, Simona Bassi, MD, Liliana Calabrese, Emilia Cocorocchio, Giovanni Martinelli

Blood (2008) 112 (11): 3607.

https://doi.org/10.1182/blood.V112.11.3607.3607

Published: 2008

Journal Articles

Red Marrow Dosimetry and Stem Cell Reinfusion in High Dose 90 Y - Ibritumomab Tiuxetan.

Anna Vanazzi, Daniele Laszlo, Marta Cremonesi, Chiara Maria Grana, Stefano Papi, Alessandra Alietti, Sarah Jayne Liptrott, Liliana Calabrese, Giovanni Paganelli, Giovanni Martinelli

Blood (2008) 112 (11): 2187.

https://doi.org/10.1182/blood.V112.11.2187.2187

Published: 2008

Journal Articles

Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano

Simona Bassi, MD, Federica Gigli, Cristina Rabascio, Simona Sammassimo, Patrizia Mancuso, Emilia Cocorocchio, Paola Bertazzoni, Daniele Laszlo, Giancarlo Pruneri, Liliana Calabrese, Maria Teresa Lionetti, Anna Vanazzi, MD, Alessandra Alietti, Luca Nassi, Alberto Agazzi, Rocco Pastano, Fedro Alessandro Peccatori, Giovanni Martinelli

Blood (2008) 112 (11): 5016.

https://doi.org/10.1182/blood.V112.11.5016.5016

Published: 2008

Journal Articles

High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.

Anna Vanazzi, MD, Pier Francesco Ferrucci, MD, Chiara Grana, MD, Marta Cremonesi, MPh, Margherita Clerici, RN, Davide Radice, ST, Stefano Papi, PhD, Liliana Calabrese, DM, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 1890.

https://doi.org/10.1182/blood.V110.11.1890.1890

Published: 2007

Journal Articles

Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin’s Lymphoma (HL): A Single Centre Experience.

Emilia Cocorocchio, MD, Fedro A. Peccatori, MD, Federica Gigli, MD, Simona Bassi, MD, Luca Nassi, MD, Liliana Calabrese, DSc, Laura Travaini, MD, Gaia Piperno, MD, Lorenzo Preda, MD, Giancarlo Pruneri, MD, Sarah J. Liptrott, BN, Alessandra Alietti, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 4463.

https://doi.org/10.1182/blood.V110.11.4463.4463

Published: 2007

Journal Articles

Expression of the Human Concentrative Nucleotide Transporter (hCNT1) Gene Correlates with Clinical Response in Patients Affected by Waldenstrom’s Macroglobulinemia (WM), Undergoing a Combination Treatment with Cladribine (2-CdA) and Rituximab.

Daniele Laszlo, MD, Cristina Rabascio, DSc, Giovanna Andreola, MD, Luca Saronni, DSc, Liliana Calabrese, DSc, Luigi Rigacci, MD, Alberto Fabbri, MD, Antonello Pinto, MD, Ferdinando Frigeri, MD, Atto Billio, MD, Graziella Pinotti, MD, Simona Sammassimo, MD, Giovanni Martinelli, MD

Blood (2007) 110 (11): 1357.

https://doi.org/10.1182/blood.V110.11.1357.1357

Published: 2007

Journal Articles

Valganciclovir Is Safe and Effective as Pre-Emptive Treatment for CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation.

Rocco Pastano, MD, Federica Gigli, MD, Giovanna Andreola, MD, Liliana Calabrese, DM, Fedro Peccatori, MD, Giovanni Martinelli, MD

Blood (2006) 108 (11): 5300.

https://doi.org/10.1182/blood.V108.11.5300.5300

Published: 2006

Journal Articles

High Dose 90 Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.

Anna Vanazzi, MD, Pier Francesco Ferrucci, MD, Chiara Grana, MD, Marta Cremonesi, MPH, Margherita Clerici, RN, Davide Radice, ST, STefano Papi, Liliana Calabrese, DM, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2006) 108 (11): 2720.

https://doi.org/10.1182/blood.V108.11.2720.2720

Published: 2006

Journal Articles

Tissue Microarray (TMA) Study in DLBC Lymphomas (DLBCL): Could the Extranodal Origin Affect the Prognostic Impact of the Analysis?.

Daniele Laszlo, MD, Giancarlo Pruneri, MD, Giovanna Andreola, MD, Davide Radice, ST, Liliana Calabrese, DM, Alessandra Alietti, MD, Alberto Agazzi, MD, Anna Vanazzi, MD, Giovanni Martinelli, MD

Blood (2006) 108 (11): 2037.

https://doi.org/10.1182/blood.V108.11.2037.2037

Published: 2006

Journal Articles

High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.

Anna Vanazzi, MD, Pierfrancesco Ferrucci, MD, Mahila Ferrari, Liliana Calabrese, Marta Cremonesi, Mirco Bartolomei, MD, Giovanni Paganelli, MD, Giovanni Martinelli, MD

Blood (2005) 106 (11): 488.

https://doi.org/10.1182/blood.V106.11.488.488

Published: 2005

Journal Articles

High Dose Chemotherapy with Autologous Stem Cell Support Is Effective in Resistant and Refractory Hodgkin Lymphoma. A Single Center Analysis.

Emilia Cocorocchio, MD, Fedro Peccatori, MD, Simona Bassi, MD, Federica Gigli, MD, Davide Radice, Giancarlo Pruneri, MD, Cristina Rabascio, Liliana Calabrese, Giovanni Martinelli, MD

Blood (2005) 106 (11): 5506.

https://doi.org/10.1182/blood.V106.11.5506.5506

Published: 2005

NARROW

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia and Second Malignancy Following Yttrium-90 Ibritumomab Tiuxetan: 10-Year Single-Institution Experience of 138 Consecutive Patients

Efficacy of 90 yttrium-Ibritumomab Tiuxetan in Extranodal Marginal-Zone Lymphoma,

A New Induction Combination Therapy (ThalDoDex) for Multiple Myeloma. Preliminary Results of a Phase II Study

90 y-Ibritumomab Tiuxetan or Purine Analogues Severely Affect Peripheral Blood Stem Cell Mobilization: An Analysis On 248 Patients.

Efficacy of 90 Y - Ibritumomab Tiuxetan in Relapsed or Refractory Primary Gastric Non Hodgkin Lymphoma

Rituximab and 2-Cda Activity in CLL/SLL Patients: An Update of Pharmacogenomic and Clinical Results

Interim 18 f[FDG] Positron Emission Tomography in Patients with Diffuse Large B-Cell Lymphoma

Red Marrow Dosimetry and Stem Cell Reinfusion in High Dose 90 Y - Ibritumomab Tiuxetan.

Evolving First-Line Treatments -from Chemotherapy to Immunotherapy Alone- in 143 Consecutive Follicular Lymphoma Patients Treated in the Last 14 Years at the European Institute of Oncology, Milano

High Dose 90Yttrium Ibritumomab Tiuxetan with PBSC Support in Refractory-Resistant NHL Patients.

Combined VBM Chemotherapy and Involved Field (IF) Radiotherapy in Early Stage Hodgkin’s Lymphoma (HL): A Single Centre Experience.

Expression of the Human Concentrative Nucleotide Transporter (hCNT1) Gene Correlates with Clinical Response in Patients Affected by Waldenstrom’s Macroglobulinemia (WM), Undergoing a Combination Treatment with Cladribine (2-CdA) and Rituximab.

Valganciclovir Is Safe and Effective as Pre-Emptive Treatment for CMV Infection in Allogeneic Hematopoietic Stem Cell Transplantation.

High Dose 90 Yttrium Ibritumomab Tiuxetan (Zevalin) with PBSC Support in Refractory-Resistant NHL Patients: A Phase I/II Study.

Tissue Microarray (TMA) Study in DLBC Lymphomas (DLBCL): Could the Extranodal Origin Affect the Prognostic Impact of the Analysis?.

High Dose Zevalin (90Yttrium Ibritumomab Tiuxetan) Treatment with PBSC Support in Refractory-Resistant NHL Patients: Preliminary Results of a Phase I/II Study.

High Dose Chemotherapy with Autologous Stem Cell Support Is Effective in Resistant and Refractory Hodgkin Lymphoma. A Single Center Analysis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only